Galen has strengthens its product base by acquiring swedish  breakthrough cancer pain product  (BTcP) Abstral from  Orexo – a listed swedish pharma company partly owned by Danish Diabates-giant Novo.

http://finance.yahoo.com/news/galena-biopharma-acquires-abstral-r-070000289.html

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years :)

 

What do you say?

Set your Twitter account name in your settings to use the TwitterBar Section.